Sunday, November 30, 2025 11/30/2025

Thiol Isomerases and Oxidant Stress in Thrombus Formation

Award Number: R01HL167383
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/15/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Thiol Isomerases and Oxidant Stress in Thrombus Formation - Project Summary Thiol isomerases (TIs) represent a previously unrecognized layer of regulation of thrombus formation. The role of protein disulfide isomerase (PDI) family TIs in thrombosis has now been shown in animal studies using genetically modified mice, antibodies that block TI activity, and small molecule antagonists of TIs. We have used a PDI inhibitor prophylactically in a phase II study of patients with advanced malignancy to reduce cancer- associated thrombosis. Yet despite the rapid progress in the therapeutic development of PDI antagonists, a comprehensive explanation of how TIs promote clot formation has yet to emerge. TIs are fundamentally endoplasmic reticulum (ER) redox sensors. Fueled by the oxidative environment of the ER, they use oxidants to generate disulfides in nascent proteins. The studies described in this application will evaluate whether this fundamental property of PDI family TIs powers their prothrombotic potential by translating vascular oxidants into a thrombotic response. We will evaluate the hypothesis that oxidants generated in disease states promote PDI sulfenylation and formation of oxidized PDI (oxPDI), which promotes thrombus formation through disulfide formation in extracellular substrates. How the redox environment induces oxidative cysteine modifications in PDI, which in turn control PDI function and enables PDI to oxidize thrombotic targets, will be assessed using novel probes of cysteine modifications and chemical-proteomic approaches (Aim 1). These experiments will define the cysteine modifications that PDI undergoes in the circulation and identify substrates oxidized by oxPDI during platelet activation. Approaches described in Aim 2 will use structure-function studies of PDI mutants and smFRET to define the molecular determinants of oxidant-induced disulfide formation in PDI. PDI mutants deficient in oxidant-induced disulfide formation will be used in murine models of thrombus formation to determine the role of oxidant-induced PDI disulfide formation in thrombosis. How oxPDI is released into the extracellular environment to interact with the thrombotic machinery will be determined by evaluating the role of the unfolded protein response (UPR) in promoting thrombus formation in an alveolus-on-chip model of pulmonary inflammation (Aim 3). These studies will define specific UPR and TI pathways that activate coagulation and determine how their activation causes a prothrombotic transformation of endothelium that results in microvascular occlusion. The premise that inhibition of UPR receptors such as IRE1a, PERK, and ATF6 impairs thrombus formation will be tested. Similarly, PDI and ERp46 will be evaluated as antithrombotic targets. This program will test a new model by which to conceptualize the function of TIs in thrombus formation based on understanding of determinants of redox environment and TI cysteine modifications. Validation of this model will lead to the identification of new biomarkers and therapeutic targets for managing thrombotic disease in the context of oxidant stress.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $669,852 )
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Blood Diseases and Resources Research	001	2	9/15/2025	NON-COMPETING CONTINUATION	$66,985
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Blood Diseases and Resources Research	000	2	5/1/2025	NON-COMPETING CONTINUATION	$602,867
														Subtotal = $669,852

Issue Date FY: 2024 ( Subtotal = $688,077 )
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Blood Diseases and Resources Research	000	1	5/15/2024	NEW	$621,093
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Blood Diseases and Resources Research	001	1	6/28/2024	NEW	$66,984
														Subtotal = $688,077

Grand Total All Awards = $1,357,929

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Thiol Isomerases and Oxidant Stress in Thrombus Formation

Award Number: R01HL167383

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/15/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer